Skip to content

FDA approves 1st new treatment for essential thrombocythemia in nearly three decades
Posters not to miss: Cellular therapy edition
Dose-dense mini-CVD plus inotuzumab ozogamicin, blinatumomab demonstrates deep, durable responses in relapsed or refractory B-ALL
FDA receives sNDA for selinexor, ruxolitinib in myelofibrosis
LYT-200 receives FDA Fast Track Designation for relapsed or refractory high-risk MDS

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Cellular Therapy

SOHO 2026 Cellular Therapy Meetings / Conferences

Posters not to miss: Cellular therapy edition

by Krish Patel, MD
September 24, 2026
0 Comments

Acute Lymphoblastic Leukemia News SOHO 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences News

Session sparks debate on whether chemotherapy is needed in ALL care

by Elias Jabbour, MD
September 7, 2026
0 Comments

Acute Lymphoblastic Leukemia News Leukemia News SOHO 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia News Video Interviews

Dr. DiPersio previews the SOHO 2026 ALL session to be held on Wednesday, September 9

by SOHO Insider Editors
September 2, 2026
0 Comments

Cellular Therapy Leukemia Acute Myeloid Leukemia

Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

by Patrick Daly
August 26, 2026
0 Comments

EHA 2026 Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas News Video Interviews

Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL

by SOHO Insider Editors
August 21, 2026
0 Comments

Cellular Therapy Leukemia Chronic Lymphocytic Leukemia Lymphoma Indolent B-Cell Lymphomas News

Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL

by Kerri Fitzgerald
August 20, 2026
0 Comments

Cellular Therapy Lymphoma

Post-transplantation outcomes have improved for Hodgkin lymphoma

by Leah Sherwood
August 13, 2026
0 Comments

EHA 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences

Nanobody-based anti-CD5 CAR T agent improves efficacy in relapsed or refractory T-cell ALL

by Patrick Daly
June 30, 2026
0 Comments

Past Sessions Community Oncology Cellular Therapy Multiple Myeloma News Video Interviews

Dr. Jeffery Matous presents ‘Managing access to novel agents in the community setting’

by SOHO Insider Editors
June 30, 2026
0 Comments

ASCO 2026 Cellular Therapy Multiple Myeloma News

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

by Patrick Daly
June 8, 2026
0 Comments

1
2
3
...
9

Top Categories

Cellular Therapy

83

Leukemia

134

Lymphoma

142

Multiple Myeloma

120

Myelodysplastic Syndromes

50

Myeloproliferative Neoplasms

38

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Cellular Therapy

Posters not to miss: Cellular therapy edition

Session sparks debate on whether chemotherapy is needed in ALL care

Dr. DiPersio previews the SOHO 2026 ALL session to be held on Wednesday, September 9

Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL

Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL

Post-transplantation outcomes have improved for Hodgkin lymphoma

Nanobody-based anti-CD5 CAR T agent improves efficacy in relapsed or refractory T-cell ALL

Dr. Jeffery Matous presents ‘Managing access to novel agents in the community setting’

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

FDA approves 1st new treatment for essential thrombocythemia in nearly three decades

Posters not to miss: Cellular therapy edition

Dose-dense mini-CVD plus inotuzumab ozogamicin, blinatumomab demonstrates deep, durable responses in relapsed or refractory B-ALL

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Cellular Therapy

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms